Opioid maintenance therapy restores CD4+ T cell function by normalizing CD4+CD25high regulatory T cell frequencies in heroin user

Brain, Behavior, and Immunity

Volumn 26, Issue 6, 2012, Pages 972-978

  Riß, Gina Lucia ^a   Chang, Dae In ^b   Wevers, Carolin ^a   Westendorf, Astrid M ^a   Buer, Jan ^a   Scherbaum, Norbert ^b   Hansen, Wiebke ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Addiction; Buprenorphine; Heroin; Immune suppression; Methadone; Regulatory T cells

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; LEVOMETHADONE; METHADONE; NALOXONE;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEROIN DEPENDENCE; HUMAN; IMMUNE RESPONSE; MAINTENANCE THERAPY; MALE; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; BUPRENORPHINE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SEPARATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; HEROIN DEPENDENCE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; T-LYMPHOCYTES, REGULATORY;

EID: 84863869925     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.05.008     Document Type: Article

References (31)

1. Antonilli L., Petecchia E., Caprioli D., Badiani A., Nencini P. Effect of repeated administration of heroin, naltrexone, methadone, and alcohol on morphine glucuronidation in the rat. Psychopharmacology 2005, 182:58-64.
2. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat. Rev. Immunol. 2007, 7:875-888.
3. Borner C., Warnick B., Smida M., Hartig R., Lindquist J.A., Schraven B., Hollt V., Kraus J. Mechanisms of opioid-mediated inhibition of human T cell receptor signaling. J. Immunol. 2009, 183:882-889.
4. Buer J., Westendorf A.M., Zang A.-P., He F., Hansen W., Probst-Kepper M. Mechanisms of central and peripheral T-cell tolerance: an update. Transfus. Med. Hemother. 2005, 32:384-399.
5. Carrigan K.A., Saurer T.B., Ijames S.G., Lysle D.T. Buprenorphineproduces naltrexone reversible alterations of immune status. Int. Immunopharmacol. 2004, 4:419-428.
6. Dietze K.K., Zelinskyy G., Gibbert K., Schimmer S., Francois S., Myers L., Sparwasser T., Hasenkrug K.J., Dittmer U. Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc. Natl. Acad. Sci. U S A 2011, 108:2420-2425.
7. Falek A., Donahoe R.M., Madden J.J., Shafer D.A. Opiates as immunosuppressive and genotoxic agents. Adv. Exp. Med. Biol. 1991, 288:189-201.
8. Fecho K., Nelson C.J., Lysle D.T. Phenotypic and functional assessments of immune status in the rat spleen following acute heroin treatment. Immunopharmacology 2000, 46:193-207.
9. Fontenot J.D., Rudensky A.Y. A well adapted regulatory contrivance. regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 2005, 6:331-337.
10. Gordon R.J., Lowy F.D. Bacterial infections in drug users. N. Engl. J. Med. 2005, 353:1945-1954.
11. Govitrapong P., Suttitum T., Kotchabhakdi N., Uneklabh T. Alterations of immune functions in heroin addicts and heroin withdrawal subjects. J. Pharmacol. Exp. Ther. 1998, 286:883-889.
12. Kaushik K.S., Kapila K., Praharaj A.K. Shooting up: the interface of microbial infections and drug abuse. J. Med. Microbiol. 2011, 60:408-422.
13. Klages K., Mayer C.T., Lahl K., Loddenkemper C., Teng M.W., Ngiow S.F., Smyth M.J., Hamann A., Huehn J., Sparwasser T. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010, 70:7788-7799.
14. Liang B., Workman C., Lee J., Chew C., Dale B.M., Colonna L., Flores M., Li N., Schweighoffer E., Greenberg S., Tybulewicz V., Vignali D., Clynes R. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J. Immunol. 2008, 180:5916-5926.
15. McGeachy M.J., Stephens L.A., Anderton S.M. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 2005, 175:3025-3032.
16. Misra N., Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., Kaveri S.V. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J. Immunol. 2004, 172:4676-4680.
17. Nair M.P., Laing T.J., Schwartz S.A. Decreased natural and antibody-dependent cellular cytotoxic activities in intravenous drug abusers. Clin. Immunol. Immunopathol. 1986, 38:68-78.
18. Neri S., Bruno C.M., Pulvirenti D., Malaguarnera M., Italiano C., Mauceri B., Abate G., Cilio D., Calvagno S., Tsami A., Ignaccolo L., Interlandi D., Prestianni L., Ricchena M., Noto R. Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology 2005, 179:700-704.
19. Novick D.M., Ochshorn M., Ghali V., Croxson T.S., Mercer W.D., Chiorazzi N., Kreek M.J. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J. Pharmacol. Exp. Ther. 1989, 250:606-610.
20. Oberle N., Eberhardt N., Falk C.S., Krammer P.H., Suri-Payer E. Rapid suppression of cytokine transcription in human CD4+CD25 T cells by CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-beta, and various inhibitors of TCR signaling. J. Immunol. 2007, 179:3578-3587.
21. Pacifici R., di Carlo S., Bacosi A., Pichini S., Zuccaro P. Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int. J. Immunopharmacol. 2000, 22:603-614.
22. Pfoertner S., Jeron A., Probst-Kepper M., Guzman C.A., Hansen W., Westendorf A.M., Toepfer T., Schrader A.J., Franzke A., Buer J., Geffers R. Signatures of human regulatory T cells: an encounter with old friends and new players. Genome Biol. 2006, 7:R54.
23. Regan P.M., Dave R.S., Datta P.K., Khalili K. Epigenetics of μ-opioid receptors: Intersection with HIV-1 infection of the central nervous system. J. Cell. Physiol. 2012, 227:2832-2841.
24. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., Fontenot J., Castelli L., Ye X., Treuting P., Siewe L., Roers A., Henderson W.R., Müller W., Rudensky A.Y. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28:546-558.
25. Rumi M., Colombo M., Romeo R., Boschini A., Zanetti A., Gringeri A., Mannucci P.M. Suboptimal response to hepatitis B vaccine in drug users. Arch. Intern. Med. 1991, 151:574-578.
26. Sacerdote P., Franchi S., Gerra G., Leccese V., Panerai A.E., Somaini L. Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function. Brain Behav. Immun. 2008, 22:606-613.
27. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., Shimizu J., Takahashi T., Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 2006, 212:8-27.
28. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
29. Shine D., Moll B., Emeson E., Spigland I., Harris C., Small C.B., Friedland G., Weiss S.H., Bodner A.J. Serologic, immunologic, and clinical features of parenteral drug users from contrasting populations. Am. J. Drug Alcohol Abuse 1987, 13:401-412.
30. Thomas P.T., House R.V., Bhargava H.N. Direct cellular immunomodulation produced by diacetylmorphine (heroin) or methadone. Gen. Pharmacol. 1995, 26:123-130.
31. Westendorf A.M., Fleissner D., Deppenmeier S., Gruber A.-D., Bruder D., Hansen W., Liblau R., Buer J. Autoimmune-mediated intestinal inflammation-impact and regulation of antigen-specific CD8+ T cells. Gastroenterology 2006, 131:510-524.